Gitanjali Sharma
YOU?
Author Swipe
View article: IMPACT OF ORGANIZATIONAL CULTURE ON EMPLOYEE’S PERFORMANCE AND JOB SATISFACTION IN HOTEL INDUSTRY
IMPACT OF ORGANIZATIONAL CULTURE ON EMPLOYEE’S PERFORMANCE AND JOB SATISFACTION IN HOTEL INDUSTRY Open
Background: Organisations in hotel industry rely on their workforce for optimum productivity. People contribute their own special set of values and behaviours to their organization. Establishment with positive organizational culture has be…
View article: Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Immunohistochemical Analysis of SSTR2 Expression in 35 Small Cell Lung Cancer Patient Samples
View article: Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Immunohistochemical Analysis of SSTR2 Expression in 44 Small Cell Lung Cancer Patient Samples
View article: Data from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Data from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a 95% mortality rate with no improvement to treatment in decades, and new therapies are desperately needed. PEN-221 is a miniaturized peptide–drug conjugate (∼2 k…
View article: Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
In vitro inhibition of proliferation of SCLC cells by PEN-221 or DM1
View article: Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Description of BT-984 synthesis and LC-MS/MS sample preparation
View article: Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Pharmacokinetic analysis of PEN-221 and DM1 in non-tumor bearing mice
View article: Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
In vitro inhibition of proliferation of SCLC cells by PEN-221 or DM1
View article: Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Pharmacokinetic analysis of PEN-221 and DM1 in non-tumor bearing mice
View article: Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
SSTR2 expression analysis in xenograft tissue
View article: Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Immunohistochemical Analysis of SSTR2 Expression in 44 Small Cell Lung Cancer Patient Samples
View article: Data from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Data from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a 95% mortality rate with no improvement to treatment in decades, and new therapies are desperately needed. PEN-221 is a miniaturized peptide–drug conjugate (∼2 k…
View article: Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Description of BT-984 synthesis and LC-MS/MS sample preparation
View article: Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Body weight (BW) and health observations for efficacy studies
View article: Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Immunohistochemical Analysis of SSTR2 Expression in 35 Small Cell Lung Cancer Patient Samples
View article: Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Body weight (BW) and health observations for efficacy studies
View article: Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
SSTR2 expression analysis in xenograft tissue
View article: An Aflibercept-derived Mini-VEGF-Trap as a Potential Next-Generation VEGF Inhibitor
An Aflibercept-derived Mini-VEGF-Trap as a Potential Next-Generation VEGF Inhibitor Open
View article: A review of quantum chemical studies of Frustrated Lewis Pairs
A review of quantum chemical studies of Frustrated Lewis Pairs Open
View article: Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer Open
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a 95% mortality rate with no improvement to treatment in decades, and new therapies are desperately needed. PEN-221 is a miniaturized peptide–drug conjugate (∼2 k…
View article: Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo Open
Somatostatin receptor 2 (SSTR2) is frequently overexpressed on several types of solid tumors, including neuroendocrine tumors and small-cell lung cancer. Peptide agonists of SSTR2 are rapidly internalized upon binding to the receptor and l…
View article: Platinum(<scp>iv</scp>) azido complexes undergo copper-free click reactions with alkynes
Platinum(<span>iv</span>) azido complexes undergo copper-free click reactions with alkynes Open
We report our investigations into the first examples of copper-free 1,3-dipolar cycloaddition (click) reactions of electrophiles with a Pt(iv) azido complex.
View article: A Review on Recent Developments in Desalanisation by Forward Osmosis (FO) and Reverse Osmosis (RO)
A Review on Recent Developments in Desalanisation by Forward Osmosis (FO) and Reverse Osmosis (RO) Open
Osmosis is a physical phenomenon in which solvent molecules move through a semipermeable membrane from a dilute solution towards more concentrated solution .Initially, the mechanism of osmosis through natural materials was studied but now …
View article: The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to Brain
The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to Brain Open
The challenge of effectively delivering therapeutic agents to brain has led to an entire field of active research devoted to overcome the blood brain barrier (BBB) and efficiently deliver drugs to brain. This review focusses on exploring t…